William John Sibold Sells 1,577 Shares of Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) CEO William John Sibold sold 1,577 shares of the stock in a transaction dated Monday, January 26th. The stock was sold at an average price of $492.42, for a total transaction of $776,546.34. Following the sale, the chief executive officer owned 148,497 shares of the company’s stock, valued at approximately $73,122,892.74. This represents a 1.05% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

William John Sibold also recently made the following trade(s):

• On Thursday, December 4th, William John Sibold sold 2,400 shares of Madrigal Pharmaceuticals stock. The shares were sold at an average price of $575.34, for a total value of $1,380,816.00.

Madrigal Pharmaceuticals Trading Up 3.9%

Shares of NASDAQ:MDGL traded up $18.72 on Monday, hitting $499.17. The company had a trading volume of 336,495 shares, compared to its average volume of 364,506. The firm’s 50-day simple moving average is $559.15 and its two-hundred day simple moving average is $460.34. Madrigal Pharmaceuticals, Inc. has a 1 year low of $265.00 and a 1 year high of $615.00. The company has a quick ratio of 3.26, a current ratio of 3.44 and a debt-to-equity ratio of 0.54. The firm has a market capitalization of $11.34 billion, a price-to-earnings ratio of -38.37, a P/E/G ratio of 4.66 and a beta of -1.00.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last released its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported ($5.08) earnings per share for the quarter, missing the consensus estimate of ($2.01) by ($3.07). Madrigal Pharmaceuticals had a negative net margin of 39.04% and a negative return on equity of 41.50%. Equities analysts anticipate that Madrigal Pharmaceuticals, Inc. will post -23.47 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Flagship Harbor Advisors LLC bought a new position in shares of Madrigal Pharmaceuticals in the fourth quarter worth about $29,000. Aventura Private Wealth LLC bought a new stake in Madrigal Pharmaceuticals during the 4th quarter valued at approximately $36,000. Mather Group LLC. purchased a new position in Madrigal Pharmaceuticals in the 3rd quarter worth approximately $33,000. Global Retirement Partners LLC boosted its stake in Madrigal Pharmaceuticals by 221.7% in the 3rd quarter. Global Retirement Partners LLC now owns 74 shares of the biopharmaceutical company’s stock worth $34,000 after purchasing an additional 51 shares during the period. Finally, First Horizon Corp bought a new position in Madrigal Pharmaceuticals in the 3rd quarter worth approximately $34,000. 98.50% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the stock. B. Riley raised their price target on shares of Madrigal Pharmaceuticals from $560.00 to $670.00 and gave the company a “buy” rating in a research report on Thursday, December 11th. Canaccord Genuity Group increased their target price on Madrigal Pharmaceuticals from $526.00 to $587.00 and gave the company a “buy” rating in a research note on Thursday, November 13th. TD Cowen reissued a “buy” rating on shares of Madrigal Pharmaceuticals in a report on Monday, January 12th. Wolfe Research set a $579.00 price target on Madrigal Pharmaceuticals in a research note on Tuesday, January 6th. Finally, Zacks Research downgraded Madrigal Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Monday, January 12th. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, two have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $632.64.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for cardiovascular, metabolic and liver diseases. The company’s pipeline centers on novel, liver-directed agents designed to address significant unmet medical needs, with an emphasis on nonalcoholic steatohepatitis (NASH) and related metabolic disorders.

The lead product candidate, resmetirom (MGL-3196), is an orally administered, selective thyroid hormone receptor-β agonist in Phase 3 development for the treatment of NASH.